Personalis, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About Personalis, Inc.

Personalis, Inc. (ticker: PSNL) is a U.S.-listed company trading on the NASDAQ in the United States. It operates in the intersection of cancer genomics, molecular diagnostics, and precision oncology. Founded in 2011 by a team of next-generation sequencing thought leaders from Stanford University, the company began operations that same year and has since built a niche position in advanced genomic testing for cancer. Its headquarters, which also house a CLIA-certified and CAP-accredited laboratory, are located in Fremont, California. Personalis’ business model is anchored in two main pillars. First, it develops and commercializes comprehensive tumor-profiling solutions for laboratories, clinicians, and biopharma partners. Its flagship ImmunoID NeXT platform is designed to provide a multidimensional view of the tumor microenvironment from a single tissue sample, combining exome, transcriptome, and immune-biomarker data. Second, the company has expanded into liquid biopsy through NeXT Personal, a tumor-informed assay designed to detect minimal residual disease, monitor treatment response, and track recurrence with very high sensitivity. Personalis also offers NeXT Dx, a comprehensive genomic profiling test intended to help physicians identify actionable therapies or suitable clinical trials. From a competitive standpoint, Personalis differentiates itself through a highly integrated cancer genomics approach and a particularly broad molecular readout. That positions it against other oncology diagnostics and sequencing specialists, but its competitive advantage lies in analytical depth, clinical orientation, and strong ties to pharmaceutical partners. Its customer base includes pharma and biopharma companies, diagnostics firms, universities, non-profit organizations, government entities, and cancer patients. Recent highlights include the company’s 2025 quarterly and full-year reporting cycle, which emphasized continued commercialization of NeXT Personal and ongoing expansion in clinical and research use cases. Personalis has also announced scientific publications validating test performance, as well as a commercial partnership with Myriad Genetics to broaden access to biopharma customers. For French-speaking investors, PSNL remains an innovative healthcare name exposed to the structural growth of biomarker-driven oncology and molecular testing, but still dependent on clinical adoption, reimbursement progress, and biopharma contract execution.